Literature DB >> 3118350

Effects of acetazolamide on cerebral blood flow and brain tissue oxygenation.

N A Lassen1, L Friberg, J Kastrup, D Rizzi, J J Jensen.   

Abstract

Oral administration of 1 g of acetazolamide to 8 normal subjects studied at sea level and in normoxia caused an acute increase in cerebral blood flow (CBF). During the subsequent prolonged oral treatment with 1 g of acetazolamide daily, CBF returned to normal within 2 days. The alveolar CO2 tension decreased gradually to 70% of the control value, indicating hyperventilation. At sea level hyperventilation will not increase brain oxygenation significantly in normal man, as the arterial oxygen content only increases minimally, while CBF is unchanged. At high altitude the beneficial effects of acetazolamide on the symptoms of acute mountain sickness may well be due to an improved oxygen supply to the brain, as hyperventilation will, at the low ambient PO2, cause a significant increase of the arterial oxygen content, while CBF presumably is unaffected by the drug. During hypoxia at high altitude the overall effect of prolonged acetazolamide treatment may thus be equivalent to a descent by several hundred metres.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3118350      PMCID: PMC2428264          DOI: 10.1136/pgmj.63.737.185

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  11 in total

1.  Alveolar gas composition at 21,000 to 25,700 ft. (6400-7830 m).

Authors:  M B GILL; J S MILLEDGE; L G PUGH; J B WEST
Journal:  J Physiol       Date:  1962-10       Impact factor: 5.182

2.  The effect of acetazoleamide (diamox) and ammonium chloride on acid-base balance in pulmonary emphysema: a comparative study.

Authors:  A J BARAK; M BEBER; H P JACOBI
Journal:  Am J Med Sci       Date:  1957-07       Impact factor: 2.378

3.  Effects of aminophylline and diamox alone and together on respiration and acid-base balance and on respiratory response to carbon dioxide in pulmonary emphysema.

Authors:  M GALDSTON; J GELLER
Journal:  Am J Med       Date:  1957-08       Impact factor: 4.965

4.  Amelioration of the symptoms of acute mountain sickness by staging and acetazolamide.

Authors:  W O Evans; S M Robinson; D H Horstman; R E Jackson; R B Weiskopf
Journal:  Aviat Space Environ Med       Date:  1976-05

5.  Carbon dioxide permeability of the blood-brain barrier in man. The effect of acetazolamide.

Authors:  M L Friis; O B Paulson; M M Hertz
Journal:  Microvasc Res       Date:  1980-07       Impact factor: 3.514

6.  Brain carbonic acid acidosis after acetazolamide.

Authors:  D Heuser; J Astrup; N A Lassen; B E Betz
Journal:  Acta Physiol Scand       Date:  1975-03

7.  Low doses of acetazolamide to aid accommodation of men to altitude.

Authors:  S M Cain; J E Dunn
Journal:  J Appl Physiol       Date:  1966-07       Impact factor: 3.531

8.  Carbonic anhydrase inhibition and cerebral venous blood gases and ions in man. Demonstration of increased oxygen availability to ischemic brain.

Authors:  F Gotoh; J S Meyer; M Tomita
Journal:  Arch Intern Med       Date:  1966-01

9.  Effect of acetazolamide on cerebral blood flow and cerebral metabolic rate for oxygen.

Authors:  S Vorstrup; L Henriksen; O B Paulson
Journal:  J Clin Invest       Date:  1984-11       Impact factor: 14.808

10.  The incidence, importance, and prophylaxis of acute mountain sickness.

Authors:  P H Hackett; D Rennie; H D Levine
Journal:  Lancet       Date:  1976-11-27       Impact factor: 79.321

View more
  9 in total

1.  Vasodilatory capacity of the cerebral vasculature in patients with carotid artery stenosis.

Authors:  R P H Bokkers; F J Wessels; H B van der Worp; J J M Zwanenburg; W P Th M Mali; J Hendrikse
Journal:  AJNR Am J Neuroradiol       Date:  2011-03-10       Impact factor: 3.825

2.  Effect of acetazolamide on cerebral artery blood velocity and regional cerebral blood flow in normal subjects.

Authors:  W Sorteberg; K F Lindegaard; K Rootwelt; A Dahl; R Nyberg-Hansen; D Russell; H Nornes
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

3.  Image-derived input function estimation on a TOF-enabled PET/MR for cerebral blood flow mapping.

Authors:  Mohammad Mehdi Khalighi; Timothy W Deller; Audrey Peiwen Fan; Praveen K Gulaka; Bin Shen; Prachi Singh; Jun-Hyung Park; Frederick T Chin; Greg Zaharchuk
Journal:  J Cereb Blood Flow Metab       Date:  2017-02-03       Impact factor: 6.200

4.  Effects of acetazolamide on cerebrovascular function and breathing stability at 5050 m.

Authors:  Jui-Lin Fan; Keith R Burgess; Kate N Thomas; Samuel J E Lucas; James D Cotter; Bengt Kayser; Karen C Peebles; Philip N Ainslie
Journal:  J Physiol       Date:  2012-01-04       Impact factor: 5.182

5.  Effect of acetazolamide on exercise at altitude.

Authors:  A R Bradwell; P W Dykes; J H Coote
Journal:  Sports Med       Date:  1987 May-Jun       Impact factor: 11.136

6.  Acute mountain sickness.

Authors:  A D Wright; R F Fletcher
Journal:  Postgrad Med J       Date:  1987-03       Impact factor: 2.401

7.  Effect of acetazolamide on susceptibility to central sleep apnea in chronic spinal cord injury.

Authors:  Geoffrey Ginter; Abdulghani Sankari; Mehdi Eshraghi; Harold Obiakor; Hossein Yarandi; Susmita Chowdhuri; Anan Salloum; M Safwan Badr
Journal:  J Appl Physiol (1985)       Date:  2020-02-20

8.  Acetazolamide reactivity on cerebral blood flow in patients with subarachnoid haemorrhage.

Authors:  J Shinoda; T Kimura; T Funakoshi; Y Araki; Y Imao
Journal:  Acta Neurochir (Wien)       Date:  1991       Impact factor: 2.216

9.  Positron emission tomography/magnetic resonance hybrid scanner imaging of cerebral blood flow using (15)O-water positron emission tomography and arterial spin labeling magnetic resonance imaging in newborn piglets.

Authors:  Julie B Andersen; William S Henning; Ulrich Lindberg; Claes N Ladefoged; Liselotte Højgaard; Gorm Greisen; Ian Law
Journal:  J Cereb Blood Flow Metab       Date:  2015-06-10       Impact factor: 6.200

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.